CTORNasdaqPharmaceutical PreparationsFiscal year ends September 30
CITIUS ONCOLOGY, INC.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.71−0.06 (-7.49%)
Close on Oct 19, 2026
- Market cap
- $76.65M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.9896 (−58.21%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $76.65M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.90
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$46.06M
- EPS, diluted
- -$0.47
- Book value per share
- $0.37
- Diluted shares
- 108M
Three years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
-$47.29M
Net income
-$46.06M
EPS, diluted
-$0.47
Reported periodTrailing twelve months